eligibility_summary
Eligible: women ≥18 with new FIGO III–IV epithelial ovarian/fallopian tube/peritoneal adenocarcinoma (HG serous/endometrioid, undiff, clear cell, mixed, NOS), CA125 ≥50, adequate organ function, ECOG 0–2, consent, contraception if WOCBP. Exclude: mucinous/carcinosarcoma/low‑grade/neuroendocrine, stage IV with bone/brain or lung/liver >2 cm or >3 NACT/not IDS, prior therapy/debulking, pregnancy/lactation, autoimmune/immunodeficiency/infection, chronic steroids/immunosuppressants, allergy, other cancer, CNS/CV disease, live vaccine, HIPEC/bev/PARPi/investigational, pressor contraindication.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05605535 tests adding oregovomab to standard paclitaxel/carboplatin as neoadjuvant therapy for advanced epithelial ovarian, fallopian tube, or peritoneal cancer. Interventions and mechanisms: • Oregovomab (MAb-B43.13): murine IgG1 monoclonal antibody against CA125 (MUC16). Binds tumor-associated and circulating CA125 to form immune complexes that enhance antigen uptake by dendritic cells, driving CA125-specific T- and B-cell responses, can engage Fc-mediated effector functions (ADCC/complement). Type: biologic immunotherapy. • Paclitaxel: taxane antimicrotubule agent, stabilizes microtubules causing mitotic arrest. • Carboplatin: platinum DNA crosslinker, induces DNA damage and apoptosis. Targets/cells/pathways: MUC16-positive ovarian cancer cells, antigen-presenting cells (dendritic cells), CD8+ T cells, NK cells via Fcγ receptors, microtubule dynamics/mitotic spindle, DNA damage/repair-apoptosis pathways. Placebo controls infusion effects.